Compare Intuit Inc. (INTU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Novo Nordisk A/S — how do they compare? Intuit Inc. trades at $290.2 (market cap $80.37B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 2.7× Intuit Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| INTU | NVO | |
|---|---|---|
Market Cap | $80.37B | $220.53B |
Sector | Technology | Health |
52-Week High | $807.39 | $71.70 |
52-Week Low | $255.07 | $35.29 |
Enterprise Value | $78.83B | $239.49B |
Dividend Yield | 1.63% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $291.09, down 1.26% over the past day, amid mixed technical signals and ongoing legal scrutiny. The stock shows strong fundamentals with revenue growth from $18.83B in 2025 to a projected $20.9B in 2026, net income margin improving to 21.91%, and consistent earnings beats. However, recent news highlights a 20% stock drop and multiple securities fraud investigations related to TurboTax pricing issues, creating investor uncertainty despite a bullish analyst consensus.
The outlook for INTU is cautiously optimistic given its robust financial health and AI-driven growth initiatives, but near-term risks from legal challenges and market sentiment could pressure the stock. Investors should weigh the company's solid profitability and upward earnings trajectory against potential volatility from ongoing investigations and competitive pressures in the fintech software space.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
